Clinical TrialJun 22, 2026, 08:12 AM
Clearmind Medicine Completes Part A Treatment in Phase I/II Trial for AUD
AI Summary
Clearmind Medicine Inc. announced the successful completion of treatment for all participants in Part A of its ongoing FDA-regulated Phase I/II clinical trial. The trial is evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD), with all 24 participants across four cohorts having completed treatment. The company is now assessing the data and intends to initiate the next stage of the clinical program, reflecting a significant milestone in its drug development.
Key Highlights
- Completed Part A treatment for all participants in the Phase I/II clinical trial.
- The trial is evaluating CMND-100 for Alcohol Use Disorder (AUD).
- All 24 participants across Cohorts 1 through 4 successfully completed treatment.
- Company is assessing the dataset and plans to initiate the next stage.
- Trial conducted under FDA oversight at sites including Yale and Johns Hopkins.
Price Impact
More from CMND